Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastrointest Surg. Oct 27, 2021; 13(10): 1202-1215
Published online Oct 27, 2021. doi: 10.4240/wjgs.v13.i10.1202
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Receiver operator characteristic analysis of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, Onodera’s Prognostic Nutritional Index, and Ki-67 index. A: Neutrophil-to-lymphocyte ratio; B: Platelet-to-lymphocyte ratio; C: Onodera’s Prognostic Nutritional Index; D: Ki-67 index.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Correlation between gastrointestinal stromal gastrointestinal stromal tumor size and neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, Onodera’s Prognostic Nutritional Index, and Ki-67 index. A: Neutrophil-to-lymphocyte ratio; B: Platelet-to-lymphocyte ratio; C: Onodera’s Prognostic Nutritional Index; D: Ki-67 index.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Recurrence-free survival analysis of 235 patients with primary gastrointestinal stromal tumors. The Kaplan-Meier curve analysis demonstrated worse recurrence-free survival rates for the patients presenting with (A) non-gastric origin, (B) larger tumor size, (C) higher mitotic index, or (D) high modified NIH risk.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Recurrence-free survival analysis of 235 patients with primary gastrointestinal stromal tumors. The Kaplan-Meier curve analysis demonstrated worse recurrence-free survival rates for the patients presenting with (A) a higher neutrophil-to-lymphocyte ratio, (B) higher platelet-to-lymphocyte ratio, or (C) lower Onodera’s Prognostic Nutritional Index. NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; OPNI: Onodera’s Prognostic Nutritional Index.